细胞分裂周期蛋白25B在乳腺癌中的表达及与预后的关系

The expression of cell division cycle 25B in breast carcinoma and its relationship with prognosis

目的测定细胞分裂周期蛋白25B(CDC25B)在乳腺癌组织中的表达情况,探讨其与乳腺癌预后的关系。方法应用免疫组织化学法测定111例乳腺癌组织中CDC25B的表达情况,结合随访资料,回顾性分析CDC25B的表达和预后间的关系。结果 CDC25B在乳腺癌组织中的高表达率为42.3%(47/111),其高表达患者的腋淋巴结转移率显著高于低表达患者(=0.042),且高表达患者总生存率显著低于低表达患者(=0.036);CDC25B的表达与肿瘤的大小、TNM分期关系不大(>0.05)。结论乳腺癌组织中CDC25B存在异常高表达,其可能与乳腺癌的发生、淋巴转移及预后有关,有望成为乳腺癌预后的重要参考指标。

Objective To observe the expression of cell division cycle 25B（CDC25B） in breast carcinoma and to investigate the its relationship with the development and prognosis of breast carcinoma.Methods The expression of CDC25B was detected by immunohistochemistry in 111 breast carcinoma specimens.Combined with follow-up data,the relationship of CDC25B expression with the clinical pathological characteristics and prognosis of breast carcinoma was retrospectively analyzed.Results TThe high expression rate of CDC25B in breast carcinoma was 42.3%（47/111）,and the rate of metastatic axillary lymph nodes in high expression group was obviously higher than that in the low expression group（=0.042）.What＇s more,the overall survival rate of the high expression group was significantly lower than that in the low expression group（=0.036）.However,there was no significant correlation with the tumor size or TNM stage（ 0.05）.Conclusion The expression of CDC25B in breast carcinoma is abnormally increased,and it is closely related with the development,metastasis and prognosis of breast carcinoma,and it can become a novel mark to evaluate prognosis of breast carcinoma.